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Alport syndrome is a hereditary glomerulopathy leading to
end-stage renal disease (ESRD), frequently during adoles-
cence. It is caused by the absence or abnormal composition
of the type IV collagen α3/4/5 network normally present
in the glomerular basement membrane (GBM) [1]. In the
September 2008 issue of the Journal of the American Soci-
ety of Nephrology, Katayama and colleagues reported that
bone marrow transplantation (BMT) following lethal irra-
diation with either wild-type or Col4a3−/− BM prolonged
the lifespan of Alport mice with similar efficiencies. Sub-
lethal irradiation alone also provided significant benefits
[2].
These results challenge reports fromCook’s andKalluri’s
groups suggesting that wild-type BM-derived cells ame-
liorate disease in Alport mice because they can differ-
entiate into podocytes and secrete the missing collagen
α3/4/5(IV) chains [3,4], which would basically constitute a
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curative cell-based therapeutic approach for treating Alport
glomerulopathy. Their interpretation that circulating BM-
derived cells are recruited to damaged glomeruli where they
can cross the GBM, become podocytes, secrete the miss-
ing collagen chains, repair the GBM defects and slow—if
not reverse [4]—disease progression appeared (and still
appears) incredibly fascinating. However, although these
authors reported improvements in overall kidney histol-
ogy compared with untreated or Col4a3−/− BM-treated
Alport mice, the most meaningful endpoint, i.e. age at
ESRD, was not tested in either study for reasons not ex-
plained [3,4]. This issue is critical, because a previous
study of Alport mice that received BM-derived mesenchy-
mal stem cells also improved renal histology, but there was
no delay of death from renal failure [5].
One potentially important difference between the stud-
ies of Katayama et al. and of Prodromidi et al. as well as
Sugimoto et al. is the genetic background of theAlportmice
used. Progression of Alport’s disease in mice is influenced
by the genetic background [6]. Amixed genetic background
carries the risk of spoiling the most meaningful endpoint,
i.e. the age at ESRD (Figure 1). The increased lifespan
in C57BL/6J Alport mice may be explained in part by an
‘escape phenomenon’ characterized by an alternative colla-
gen switch (Figure 2), whereas the GBM of the C57BL/6J
Alport mice used by Prodromidi et al. and Sugimoto et al.
[3,4] may be stabilized by incorporation of α5/6(IV) chains,
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Fig. 1. Age at death from renal failure in Col4a3−/− mice. Lifespan de-
pends on the genetic background. Furthermore, the standard deviation in
lifespan strongly depends on a clean genetic background (see box plot in
the middle, crossbreeding of C57BL/6J and 129 × 1/SvJ-backgrounds).
The immense standard deviation in an unclean background might con-
found interpretation of experiments, including histological evaluations.
Fig. 2. Immunostaining of different α(IV) collagen chains in Alport
mouse kidneys. The GBM deposition of the α3/4/5(IV) chains depends
on the gene defect (heterozygous or homozygous state) as well as on the
genetic background. Note the ‘escape phenomenon’ within the GBM of
C57BL/6J Col4a3−/− mice: these mice incorporate significant amounts
of α5/6(IV) chains into their GBM. This phenomenon might contribute
to the improved lifespan of Alport mice on this background (Figure 1) as
compared to the 129× 1/SvJ Alport mice, which showmuch less α5/6(IV)
incorporation.
possibly increasing the lifespans of the mice. The GBM of
the 129 × 1/SvJ Alport mice used by Katayama et al. [2]
exhibits far lower (though still detectable) incorporation
of the α5/6(IV) chains, which correlates with their rapid
progression to ESRD [7].
Cell-based therapies aim towards repairing the underly-
ing defect: here, the defective assembly of α3/4/5(IV) col-
lagen. Katayama et al. certainly shared this aim, but they
found no deposition of α3/4/5(IV) collagen in their WT
BM-transplanted Alport mice, despite the extended lifes-
pan [2]. We disagree with the claim in LeBleu and Kalluri’s
recent editorial [8] that ‘careful examination of immuno-
histochemistry and Western blot images in the study by
Katayama et al. reveals a likely faint labelling for α3 chain’.
Although both Prodromidi et al. and Sugimoto et al. con-
cluded that α3(IV) was present in the GBM of their BM-
transplanted Alport mice [3,4], neither presented definitive
supporting evidence. Focal staining for α3(IV) [3,4] does
not prove true GBM deposition; patients with X-linked Al-
port syndrome show intracellular α3(IV) mRNA and pro-
tein in podocytes that is unaccompanied by α4 or α5(IV)
[9], and similar findings have been reported in Alport dogs
[10]. Furthermore, widespread linear staining for α5(IV) in
the GBM of Sugimoto et al.’s treated Alport mice, which
they presented as evidence for α3/4/5(IV) deposition [4],
might then be irrelevant due to the alternative switch [7]
discussed above. Surprisingly, Sugimoto et al.’s untreated
Col4a3−/− mice did not show GBM staining for α5(IV)
[4]. This might be explained by an impure genetic back-
ground, with the untreated Col4a3−/− mice having some
contribution from a 129 × 1/SvJ (129) or another back-
ground. This could also explain their worse renal function
as compared to the BMTgroup, which shows the alternative
switch.
A convincing demonstration of assembly of the correct
GBM collagen IV network requires biochemical evidence
of α3/4/5(IV) chain co-assembly, such as by assaying that
chains are co-immunoprecipitated by monoclonal antibod-
ies with well-defined α(IV) chain specificities. Even as-
suming that small amounts of α3/4/5(IV) were deposited
in the Col4a3−/− mouse GBM after BMT [3,4], it is un-
likely that such a focal restoration of the correct network
would improve renal survival. Indeed, insufficient incor-
poration of α3/4/5(IV) into the GBM can lead to severe
kidney involvement in Col4a5+/− female mice, in which
∼50% of podocytes are fully capable of producing the
genuine α3/4/5(IV) collagen network [11]. Nevertheless,
Sugimoto et al. did detect α3/4/5(IV) in whole kidney
lysates. Western analyses show up to half as much α3/4/5
noncollagenous (NC1) domain monomers in the trans-
planted mutant kidneys as compared to the wild-type con-
trol kidneys. Given that the α3/4/5(IV) network is found
throughout the cortex in proximal tubules and in collecting
ducts, as well as in the GBM, widespread incorporation
of collagen IV-secreting transplanted cells throughout the
parenchyma would be needed to achieve such levels. Anal-
ysis of isolated glomeruli would be necessary to provide
convincing evidence of incorporation of the α3/4/5(IV) net-
work in GBM and this was not performed [4].
Katayama et al. show that irradiation alone provides
benefits without BMT [2], implying that a significant
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portion of the amelioration of disease reported by Cook’s
and Kalluri’s groups [3,4] might have little to do with the
transplanted cells. Some statements (one of them quoted
above) in LeBleu and Kalluri’s recent editorial [8] on
Katayama’s paper appear to be designed to weaken its im-
pact. As the data of Katayama et al.’s study challenge the
proposed concept/mechanism of BMT therapy for Alport
syndrome, a careful analysis of their data and their approach
is necessary to avoid further controversy with regard to the
importance of these studies:
1. Katayama’s study was performed in Col4a3−/− mice
on the 129× 1/SvJ background,which renders compar-
isons to data generated on the C57BL/6J background
potentially problematic. The age at the time of BMT
also differed among the studies. The different back-
grounds and ages at BMT could be responsible, in part,
for the different outcomes, given differences in timing
and severity of GBM defects and their potential effects
on the behaviour of the transplanted BM cells. Indeed,
LeBleu and Kalluri suggest that Katayama’s 129 ×
1/SvJ Alport mice, transplanted at 3 weeks, would not
have the GBM defects that are ‘a likely prerequisite
for successful cell-based therapy’ [8]. Yet results in the
two references cited [12,13] and others [6] indicate that
it is highly unlikely that at 3 weeks of age the Alport
GBM on the 129 background is normal. More impor-
tantly, there is no evidence to support the assumption
that GBM damage is a pre-requisite for a stem cell
repopulation.
2. Katayama et al. did not directly compare treatmentwith
and without BMT at a given irradiation dose. How-
ever, the finding that Col4a3−/− mice transplanted
with Col4a3−/− BM after irradiation with 8 Gy
(stands for Gray, irradiation dosage) live longer than
non-transplanted Col4a3−/− mice irradiated with 3,
6 or 7 Gy (stands for Gray, irradiation dosage) does
support the author’s interpretation of a dose-dependent
effect of irradiation.
3. Katayama et al.’s analysis of α(IV) chain expression
was limited to 7- and 11-week-old mice, only 4 or 8
weeks after BMT. The study lacks an additional later
time point such as 15 weeks of age (12 weeks after
BMT). This later time point would have allowed us
to exclude the existence of incomplete BM reconstitu-
tion and later progenitor cell migration into the kidney,
whichmight have beenmissed at the earlier time points.
4. Katayama et al. do not provide data on albuminuria,
but the BUN and serum creatinine levels (being highly
correlated with albuminuria in the Sugimoto study)
convincingly demonstrate improvement of renal func-
tion.
5. Finally, Le Bleu and Kalluri raised doubts [8] about
Katayama’s finding that irradiated mice lived longer
independent of a significant effect on interstitial fi-
brosis. However, previous studies in Col4a3−/− mice
on the 129 background have already demonstrated that
the extent of interstitial fibrosis does not correlate with
survival time [5].
In summary, despite some limitations underscoring our
lack of basic understanding of this emergent area of re-
search, the study by Katayama clearly demonstrates that
BMT as a collagen IV replacement therapy does not pro-
vide additional benefits beyond irradiation to prolong the
survival of Col4a3−/− mice on the 129 × 1/SvJ genetic
background. In agreement with a previous editorial [8], fu-
ture studies in this field should use Alport mice with a clean
genetic background. Most importantly, histological studies
should be supported by showing the numbers of animals
treated and survival curves, including standard deviations
in both, with treated and untreated mice being littermates
of each other.
Taking the above conditio sine qua non into account,
Col4a3−/− mice have been particularly useful for testing
potential therapies. As a potentially life-threatening proce-
dure, BMT will need to be demonstrated to be superior to
less dangerous drug-based therapies for Alport nephropa-
thy, some of them being broadly used as off-label therapies
throughout the world. European and American Alport reg-
istries currently investigate the long-term outcome and the
safety of these medications. Unfortunately, scientific ar-
ticles on the preliminary and controversial basic research
in Alport-mice may be misinterpreted as ‘a cure has been
found’ and editorial headlines that try to turn doubts about
the concept into a proof of the desired truth are mislead-
ing and have had unfavourable secondary effects [3,4,8].
In fact, the lay press turned the hope of a BMT cure for
Alport glomerulopathy into hype. This creates a difficult
situation for clinicians taking care of Alport patients: hopes
that clinicians cannot fulfil put an unfortunate burden on
nephrologists dealing with parents who might be desperate
because of their child’s impaired renal function and who
might be ready to take every chance to help their child.
Such hopes might turn into unjustified risks!
Our current knowledge about Alport syndrome and its
possible therapy by BMT is as yet incomplete and reveals
many open questions that need to be addressed experimen-
tally before clinical BMT studies should be considered in
Alport patients. Due to the associated risks of the BMT
procedure, it is currently only being performed in poten-
tially lethal diseases. In fact, given the perspective of renal
transplantation, Alport syndrome may not generally qual-
ify for BMT in terms of improving patient survival. Thus,
any experimental doubt that the effects of BMT are supe-
rior to those of other treatments (like drugs or irradiation)
increase the need for open-minded discussions and more
research before taking inappropriate risks that could even-
tually harm our young patients.
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